Best medical care

Phase 3Small molecule

UUniversity Hospital, Grenoble

Best medical care is one of 28 small molecule programs targeting Intracranial Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intracranial HypertensionActive, not recruiting

Type 1 DiabetesActive, not recruiting

Intracranial HypertensionPreclinical

Active, not recruiting

Type 1 DiabetesPhase 3

Active, not recruiting

Competition

Competitive Landscape

384 competitors in Type 1 Diabetes

#DrugCompanyPhaseTrials

Best medical care

UUniversity Hospital, Grenoble

Phase 3

1 2

Symlin

AstraZeneca

Preclinical

4 3

Symlin

AstraZeneca

Preclinical

3 4

Aldomet

Neurocrine Biosciences

Preclinical

2 5

Glargine

Eli Lilly

Preclinical

4 6

Pitocin

RRetrophin

Preclinical

1 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 9

Teplizumab

Sanofi

Preclinical

8 10

Mesenchymal Stem Cells

JJiangsu Topcel-KH Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

N/ARecruiting

Intracranial Hypertension

NCT06919744

Clinical

Trials by Indication[1]

Intracranial Hypertension1 trial

Intracranial Venous Stenting Evaluation in Patients With Idiopathic Intracranial Hypertension in the Early Phase

Recruiting·UUniversity Hospital, Montpellier·N/A·NCT06919744·114 enrolled

Type 1 Diabetes1 trial

Health Economic Analysis of Islet Cell Transplantation for the Stabilization of the Severe Forms of Type 1 Diabetes

Unknown status·UUniversity Hospital, Grenoble·Phase 3·NCT02854696·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Best medical care. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Best medical care compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Best medical care. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Grenoble company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Grenoble

Best medical care

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Intracranial Hypertension1 trial

Type 1 Diabetes1 trial

References

Drug Info

Quick Facts

Related News